ProteoTech Inc
12040 115th Ave NE
Kirkland
Washington
98034
United States
13 articles about ProteoTech Inc
-
ProteoTech Presents Update On Its New Product "Cognitive Claritytm" At The 12th International Conference On Alzheimer’s And Parkinson’s Diseases In Nice, France, March 18–22, 2015
3/27/2015
-
ProteoTech Is Granted Orphan Drug Designation For Systebryl™ (PTI-110) For The Treatment Of AL Amyloidosis
1/12/2015
-
ProteoTech Appoints Dr. Roger Flugel As Chief Executive Officer
1/12/2015
-
ProteoTech To Present At The Alzheimer's Association International Conference (AAIC)®, Copenhagen, Denmark, July 12-17, 2014
7/16/2014
-
ProteoTech Selected to Present at Cavendish Global Health Impact Forum
5/2/2014
-
Dr. Alan Snow From ProteoTech To Present At The XIV International Symposium On Amyloidosis
4/30/2014
-
ProteoTech's Chief Scientific Officer, Dr. Alan Snow, to Present New Data on "SystebrylTM for the Treatment of Systemic AA Amyloidosis" at the XIIIth International Symposium on Amyloidosis, Groningen, Netherlands, May 6-10, 2012
4/23/2012
-
ProteoTech and GlaxoSmithKline (China) Collaborate on Parkinson's Drug Candidate
1/3/2012
-
ProteoTech Announces Drug Development Collaborative Agreement with GlaxoSmithKline for New Parkinson's Therapeutic
12/20/2011
-
ProteoTech and Tasly Pharmaceutical Announce Alzheimer's Disease Drug Development Agreement for Exebryl-1(R)
10/4/2010
-
ProteoTech to Present at Rodman & Renshaw's 10th Annual Healthcare Conference
11/11/2008
-
ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease
8/7/2008
-
ProteoTech Team Awarded $3.1 Million LEAPS Award From Michael J. Fox Foundation For Parkinson's Research
2/13/2006